Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL), Rx Only, 12 - 5 mL Single Dose Units per box, Preservative Free, For Iontophoresis Use Only, Non-Sterile Product, Not for Injection, NUBRATORI RX, 381 Van Ness Ave# 1507, CA 90501, NDC 71300-6564-1 (box), 71300-6564-3 (vial).
Published May 7, 2025 · Recall initiated: April 15, 2025
Summary
FDA records drug Class II recall D-0392-2025, published May 7, 2025 and initiated April 15, 2025. Recalling firm: Nubratori, Inc; Status: Ongoing; Reported quantity: 20 boxes; Lot: Lot #: C04292401X1, BUD: 12/25/2025 (box). Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.
What to do
Voluntary: Firm initiated · Letter
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- Nubratori, Inc
- Distributor
- PA and CA.
- Lot
- Lot #: C04292401X1, BUD: 12/25/2025 (box).
- Risk classification
- Class II
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAClindamycin Hydrochloride Capsules, USP, 300mg, 30-count bottles, Manufactured by: Glenmark PharmaceuticalsMay 7, 2025
- FDAWegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens per Carton, For Subcutaneous UseMay 7, 2025
- FDATirofiban Hydrochloride Injection 12.5 mg/250 mL (50 mcg/mL), 250 mL single-dose container (bag), Rx only,May 7, 2025
- FDALevothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 1000 bottles, Rx Only, Manufactured for AccordMay 7, 2025
- FDATirofiban Hydrochloride Injection 5 mg/100 mL (50 mcg/mL), 100 mL single-dose container (bag), Rx only,May 7, 2025
- FDALevothyroxine Sodium Tablets, USP, 50 mcg (0.05 mg), 1000 bottles, Rx Only, Manufactured for AccordMay 7, 2025
Questions about this recall
Was Dexonto 0.4% (dexamethasone sodium phosphate) solution 20 mg/5 mL (4 mg/mL), Rx Only, 12 - 5 mL Single Dose Units per box, Preservative Free, For Iontophoresis Use Only, Non-Sterile Product, Not for Injection, NUBRATORI RX, 381 Van Ness Ave# 1507, CA 90501, NDC 71300-6564-1 (box), 71300-6564-3 (vial). recalled?
Yes. FDA published recall D-0392-2025 on May 7, 2025. Reported hazard: Labeling: Incorrect or Missing Lot and/or Expiration date: Individual vials of Dexonto 0.4%, are labeled correctly with the BUD of 12/25/2024, however, the outer box on some of the Dexonto 0.4% are labeled incorrectly with a BUD of 12/25/2025.
What should I do if I have this product?
Voluntary: Firm initiated · Letter